Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

Summary

The aim of this study is to evaluate the safety, tolerability, and pharmacokinetics of two ISIS 113715 subcutaneous doses (15 mg and 30 mg/day) in combination with oral antidiabetic agents (OAD) versus OAD + placebo in patients with inadequately controlled type 2 diabetes, despite ongoing maximal treatment with OAD.

Timeline

Start

2006-05-01

Primary completion

2007-02-01

Completion

2007-03-01

Outcome

Outcome not reported

Stopped: “study was never started due to regional geopolitical conflict”

Drugs

Indications